Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events
Top Cited Papers
- 9 April 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (14), 1650-1655
- https://doi.org/10.1161/01.cir.0000013777.21160.07
Abstract
Background— We studied whether aspirin resistance, defined as failure of suppression of thromboxane generation, increases the risk of cardiovascular events in a high-risk population. Methods and Re...Keywords
This publication has 19 references indexed in Scilit:
- Vitamin E Supplementation and Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Cyclooxygenases-1 and −2 of Endothelial Cells Utilize Exogenous or Endogenous Arachidonic Acid for Transcellular Production of ThromboxanePublished by Elsevier ,1996
- Aspirin as an Antiplatelet DrugNew England Journal of Medicine, 1994
- Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patientsThrombosis Research, 1993
- The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- A Comparison of Two Doses of Aspirin (30 mg vs. 283 mg a Day) in Patients after a Transient Ischemic Attack or Minor Ischemic StrokeNew England Journal of Medicine, 1991
- Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells.Journal of Clinical Investigation, 1984
- Synthesis of Prostacyclin from Platelet-derived Endoperoxides by Cultured Human Endothelial CellsJournal of Clinical Investigation, 1980